Evaluating Sodium Butyrate's Effect on Menstrual Symptoms in Women
Official title: The Effect of Sodium Butyrate on Menstrual Symptoms in Women
Run by Northwestern University · NCT06653426 · Data updated 2026-11-12
This study is testing if taking Sodium butyrate every day can help women with painful menstrual symptoms feel better over 12 weeks.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 15 (estimated) |
| Sponsor | Northwestern University Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Status | Recruiting |
| Started | October 1, 2024 |
| Main results expected | October 2026 |
| Study ends | December 2026 |
| Registry record updated | April 29, 2026 |
| Trial ID | NCT06653426 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 18 and older who experience regular or irregular menstruation with moderate to severe menstrual symptoms.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or post-menopausal will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to assess the impact of daily Sodium butyrate (NaBu) supplementation on menstrual symptoms in women over a 12-week period. The researchers hypothesize that NaBu will alleviate common menstrual symptoms such as cramping, back pain, and mood swings by inhibiting the aromatase enzyme involved in estrogen production. Participants will be women aged 18 and older who experience significant menstrual symptoms. The study will measure changes in symptom severity before and after the intervention.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary approach to significantly reduce menstrual symptoms for women.
How similar studies have gone: While the specific use of Sodium butyrate for menstrual symptoms is novel, other studies have explored dietary supplements for similar conditions with varying degrees of success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years or older. * Menstruating regularly or irregularly * Experiencing menstrual symptoms with an average baseline symptom score of at least 3 on a scale of 0 to 10 for at least one symptom during the initial pre-study rating period. Exclusion Criteria: * Pregnant or breastfeeding patient, attempting or anticipating pregnancy. * Patient with a history of bloating or a sensitive gut (food intolerance) who needs lower fiber levels. * Patients with known lactose intolerance, other fermentable oligo-, di-, and mono-saccharides, and polyols (FODMAP) intolerances, or small intestinal bacterial overgrowth (SIBO). * Patients who would require taking daily antacids for the duration of the study. * Patients with known or suspected chronic hypertension. * Post-menopausal patients
Where it's running
-
Northwestern University - Northwestern Medicine, Lavin Family Pavilion
Chicago, Illinois, United States Recruiting
Study contacts
- Principal investigator: Magdy P Milad, MD MS — Northwestern Medicine
- Study coordinator: juan A avitia, MS
- Email: juan.avitia1@nm.org
- Phone: 312-694-6447
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effera doses to reduce menstrual cramps and improve mood
This study tests whether taking different doses of Effera (a lactoferrin supplement) daily for 12 weeks reduces menstrual cramps and improves mood, gastrointestinal symptoms, and overall well‑being in women ages 18–40.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.